DEEPAKCHEM (DEEPAKCHEM) Fair Value & Analysis
IN · Market cap ₹869M
Fair value as of: Jul 5, 2026
From 12 valuation models · updated today
Share price −4.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹69.50 – ₹169.10 · fair‑value band ₹80.74 – ₹149.94 · the ₹79.99 price screens below the ₹115.34 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
DEEPAKCHEM (DEEPAKCHEM) currently trades at ₹79.99, while our model-based Fair Value estimate is ₹115.34 — implying the stock looks roughly 44.2% undervalued today. We read business quality at 35/100 (below-average quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, DEEPAKCHEM generated revenue of ₹676M at a net margin of 12.2%. Revenue declined 10.1% year over year. It earns a return on equity of 15.7%. Net debt stands at ₹3.6M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹80.74 (bear case) to ₹149.94 (bull case); at ₹79.99, the current price sits below that range. The share trades about 53% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
DEEPAKCHEM reported revenue of ₹676M in FY2026 versus ₹541M in FY2022, a compound +5.7%/yr. Reported net income was ₹82.5M in FY2026, compounding +18.2%/yr from FY2022.
Is DEEPAKCHEM fairly valued? → Check now
Explore undervalued stocks
Frequently asked questions
Is DEEPAKCHEM (DEEPAKCHEM) undervalued?
What is the fair value of DEEPAKCHEM?
What is the quality score of DEEPAKCHEM?
What is the revenue of DEEPAKCHEM (DEEPAKCHEM)?
What is the net profit margin of DEEPAKCHEM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.